Investigational Site Number :3800001

Milan 20141

0 studies enrolling now · 21 studies all time

What they study most

Amyotrophic Lateral Sclerosis, Breast Cancer, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Dermatitis Atopic, Giant Cell Arteritis, Hemophilia, Hemophilia A, Malignant Solid Tumor, Myasthenia Gravis, Non-relapsing Secondary Progressive Multiple Sclerosis, Non-small Cell Lung Cancer Metastatic, Polymyalgia Rheumatica

Studies at this site

• Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A — Running, not enrolling
• Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B — Running, not enrolling
• SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients — Stopped early
• A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia — Running, not enrolling
• A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2 — Stopped early
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) — Completed
• Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — Completed
• Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer — Stopped early
• Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A — Completed
• Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis — Stopped early
• Observational Evaluation of Atopic Dermatitis in Pediatric Patients — Running, not enrolling
• Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES) — Completed
• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) — Completed
• Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) — Stopped early
• Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA) — Stopped early
• A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors — Completed
• Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica — Stopped early
• Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA — Stopped early
• Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period — Completed
• Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis — Completed
• Effect of Efpeglenatide on Cardiovascular Outcomes — Stopped early